GSK2485852

**GSK2485852** is an investigational small molecule antiviral drug developed by GSK (formerly GlaxoSmithKline) for the treatment of chronic hepatitis C virus (HCV) infection. It acts as a non-nucleoside inhibitor (NNI), specifically targeting the NS5B RNA-dependent RNA polymerase of HCV at palm site 2, thereby inhibiting viral replication. Preclinical and early clinical studies demonstrated potent activity against multiple HCV genotypes and a high genetic barrier to resistance, with favorable in vitro resistance profiles compared to earlier NNIs such as HCV‑796[8][6]. In phase I clinical trials, it was well-tolerated and showed significant reductions in HCV RNA at higher doses[5]. However, development has been discontinued after phase I trials for hepatitis C[7][1][2].

Other names

[4-({[5-Cyclopropyl-2-(4-Fluorophenyl)-3-(Methylcarbamoyl)-1-Benzofuran-6-Yl](Methylsulfonyl)amino}methyl)-2-Fluorophenyl]boronic acidB-(4-(((5-cyclopropyl-2-(4-fluorophenyl)-3-(methylamino)carbonyl)-6-benzofuranyl)(methylsulfonyl)amino)methyl)-2-fluorophenyl)boronic acidUNII 6G04C5ZNQJUNII6G04C5ZNQJUNII-6G04C5ZNQJCHEMBL3121193CHEMBL-3121193CHEMBL 3121193